RxDoctor Payments Data

Patrick Gillespie, MD

Family Medicine · Washington, LANPI 1902850084

Payments from drug & device makers

$785in general payments, 2019–2025

Across 61 payments — averaging $12.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$179
  • Merck$101
  • GSK$79
  • AstraZeneca$73
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$68
  • Pfizer$55
  • plus $230 from 11 others

What the payments were for

  • Food & beverage$72592%
  • Education$608%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$785 in reported general payments places this provider in the 50th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$137,335
Medicare patients
575
Services billed
1,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$94,621
EliquisApixaban74$33,422
LinzessLinaclotide57$32,100
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$31,252
MounjaroTirzepatide16$26,207
JardianceEmpagliflozin32$19,643
Combivent RespimatIpratropium/Albuterol Sulfate36$17,677
XareltoRivaroxaban33$16,344
OzempicSemaglutide12$10,651
MyrbetriqMirabegron23$9,659
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen373$7,703
Spiriva HandihalerTiotropium Bromide14$7,181
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$6,311
Pantoprazole Sodium498$5,898
SymbicortBudesonide/Formoterol Fumarate29$5,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$33,42274 claims
AbbVieLinzess$179$32,10057 claims
GSKTrelegy Ellipta$79$31,25238 claims
Lilly USA, LLCMounjaro$13$26,20716 claims
AstraZenecaSymbicort$73$5,88129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Washington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →